AxSpA
Largest, most representative Axial Spondyloarthritis data registry available for licensing, analytics, and collaboration
Research-Grade RWD in AxSpA
Disease with no cure
With no cure for AxSpA, early diagnosis and effective treatment are the best ways to help reduce damaging effects and improve patients’ quality of life.
36,000+*
AxSpA patients followed prospectively with deep clinical, lab, and other linked data
*Counts complete through Q2 2024
370,000+*
AxSpA patients in the OM1 Real-World Data Cloud that can be used for modeling, analysis, and other research purposes
Specialized Data
Why OM1 AxSpA?
Sample Use Cases
» Feasibility |
» Comparative Effectiveness |
» Passive Safety |
» Natural History |
Webinar: Real-World Data for R&D for Autoimmune & Chronic Diseases
Posters
Starzyk K, Kumparatana P, Meng R, Probst J. Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice. ACR Convergence, November 12-14, 2022.
Award-Winning Research Team
Our team of award-winning researchers have authored hundreds of publications, including scientific posters, articles in peer-reviewed journals, white papers, and books.